Latest publications

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib. Kwatra SG, De Bruin-Weller M, Silverberg JI, Lio P, Deleuran M, Aydin H et al. Acta Derm Venereol 2024 May 06; 104:adv18452

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis. Simpson EL, De Bruin-Weller M, Hong HC, Staumont-Sallé D, Blauvelt A, Eyerich K et al. Dermatol Ther (Heidelb) 2024 May; 14(5):1145-1160

Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2). Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, De Bruin-Weller MS, Ständer S et al. Dermatol Ther (Heidelb) 2024 May; 14(5):1127-1144

The pleiotropic role of IL-13 in AD pathogenesis. Dekkers C, De Bruin-Weller M et al. Br J Dermatol 2024 Apr 25

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry. Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS et al. J Am Acad Dermatol 2024 Apr 21

House dust mite sublingual allergen immunotherapy tablet is safe and well-tolerated in Dutch clinical practice. Tempels-Pavlica Ž, Aarts MCJ, Welsing PMJ, Van der Meer AN, Van der Zwan LP, Uss E et al. Front Allergy 2024; 5:1355324

Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy. Achten R, Thijs J, Van der Wal M, Van Luijk C, Bakker D, Knol E et al. Clin Exp Allergy 2024 Apr; 54(4):241-252

Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay Registry. Kamphuis E, Boesjes CM, Loman L, Kamsteeg M, Haeck I, Van Lynden-van Nes AMT et al. Acta Derm Venereol 2024 Feb 07; 104:adv19454

Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis. Clabbers J, Boesjes C, Spekhorst L, Van Gisbergen MW, Maas E, Marshall J et al. J Allergy Clin Immunol 2024 Apr; 153(4):1155-1161.e4

Mental Health of School-Aged Children Treated with Propranolol or Atenolol for Infantile Hemangioma and Their Parents. Hermans MM, Schappin R, De Laat PCJ, Mendels EJ, Breur JMPJ, Langeveld HR et al. Dermatology 2024; 240(2):216-225

Differential dynamics of TARC during JAK-inhibitor therapy compared to biological therapies targeting type 2 inflammation. Boesjes CM, Bakker DS, Knol EF, De Graaf M, Van Wijk F, De Bruin-Weller MS et al. Clin Exp Allergy 2024 Apr; 54(4):294-296

Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis. Silverberg JI, De Bruin-Weller M, Calimlim BM, Hu X, Ofori SA, Platt AM et al. Dermatitis 2023 Dec 18

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials. Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S et al. Lancet 2024 Jan 13; 403(10422):147-159

Effectiveness of antibacterial therapeutic clothing vs. nonantibacterial therapeutic clothing in patients with moderate-to-severe atopic dermatitis: a randomized controlled observer-blind pragmatic trial (ABC trial). Ragamin A, Schappin R, De Graaf M, Tupker RA, Fieten KB, Van Mierlo MMF et al. Br J Dermatol 2024 Feb 16; 190(3):342-354

Prevalence of chronic urticaria and healthcare usage of patients with the condition in primary care: a population-based study in the Netherlands. Soegiharto R, Westmeijer M, Boekema-Bakker N, Groenewegen IAM, Knulst AC, Van den Reek JMPA et al. Br J Dermatol 2024 Jan 23; 190(2):287-289